Trial Profile
BEAM +/- ibritumomab tiuxetan in patients with aggressive lymphoma undergoing ASCT
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2012
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 10 Jul 2012 New trial record
- 17 Jun 2012 Results presented at the 17th Congress of the European Haematology Association.